Literature DB >> 25749850

In vivo study of novelly formulated porcine-derived fibrinogen as an efficient sealant.

Zhang Liu1, Lidong Guan, Kang Sun, Xujun Wu, Ling Su, Jifeng Hou, Miao Ye, Weihong Huang, Hongbing He.   

Abstract

Fibrinogen has been used as surgical sealant in the clinical setting for decades. The application of human plasma-derived fibrinogen is limited due to high cost and the risk of prion and virus infection. We developed a novel arginine-formulated fibrinogen from cryoprecipitates of porcine plasma. This porcine-derived fibrinogen exhibited excellent stability during sterilization and better hemostatic efficacy than a leading commercial hemostatic product in a nonlethal hemorrhage model. Therefore, it has the potential to be more economical and readily available while having a decreased risk of human blood-borne pathogen transmission.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25749850     DOI： 10.1007/s10856-015-5438-y

Source DB:  PubMed          Journal:  J Mater Sci Mater Med        ISSN： 0957-4530            Impact factor:   3.896


  24 in total

Review 1.  Role of arginine in protein refolding, solubilization, and purification.

Authors:  Kouhei Tsumoto; Mitsuo Umetsu; Izumi Kumagai; Daisuke Ejima; John S Philo; Tsutomu Arakawa
Journal:  Biotechnol Prog       Date:  2004 Sep-Oct

2.  Determination of porcine fibrinogen in rat and dog plasma after intraperitoneal injection of a porcine-derived fibrin glue by fluorescein-labeled assay method: Comparison with isotope-labeled assay method.

Authors:  Ying Xie; Hongbing He; Guorong Fan; Yutian Wu
Journal:  J Pharm Biomed Anal       Date:  2011-09-16       Impact factor: 3.935

3.  Dry fibrin sealant dressings reduce blood loss, resuscitation volume, and improve survival in hypothermic coagulopathic swine with grade V liver injuries.

Authors:  J B Holcomb; A E Pusateri; R A Harris; T J Reid; L D Beall; J R Hess; M J MacPhee
Journal:  J Trauma       Date:  1999-08

4.  Fibrinogen stability under surfactant interaction.

Authors:  Natalia Hassan; Leandro R S Barbosa; Rosangela Itri; Juan M Ruso
Journal:  J Colloid Interface Sci       Date:  2011-06-15       Impact factor: 8.128

5.  The conversion of fibrinogen to fibrin: recombinant fibrinogen typifies plasma fibrinogen.

Authors:  O V Gorkun; Y I Veklich; J W Weisel; S T Lord
Journal:  Blood       Date:  1997-06-15       Impact factor: 22.113

6.  Effect of dry fibrin sealant dressings versus gauze packing on blood loss in grade V liver injuries in resuscitated swine.

Authors:  J B Holcomb; A E Pusateri; R A Harris; N C Charles; R R Gomez; J P Cole; L D Beall; V Bayer; M J MacPhee; J R Hess
Journal:  J Trauma       Date:  1999-01

7.  Fibrin glue from stored human plasma. An inexpensive and efficient method for local blood bank preparation.

Authors:  W D Spotnitz; P D Mintz; N Avery; T C Bithell; S Kaul; S P Nolan
Journal:  Am Surg       Date:  1987-08       Impact factor: 0.688

8.  Randomised trial of single and repeated fibrin glue compared with injection of polidocanol in treatment of bleeding peptic ulcer.

Authors:  P Rutgeerts; E Rauws; P Wara; P Swain; A Hoos; E Solleder; J Halttunen; G Dobrilla; G Richter; R Prassler
Journal:  Lancet       Date:  1997-09-06       Impact factor: 79.321

9.  The safety of fibrin sealants.

Authors:  Christine Joch
Journal:  Cardiovasc Surg       Date:  2003-08

10.  Efficacy and safety of TachoSil as haemostatic treatment versus standard suturing in kidney tumour resection: a randomised prospective study.

Authors:  Stefan Siemer; Sven Lahme; Stefan Altziebler; Stefan Machtens; Walter Strohmaier; Hans-W Wechsel; Peter Goebell; Nicolaus Schmeller; Ralph Oberneder; Jens-Uwe Stolzenburg; Hermann Becker; Werner Lüftenegger; Vilhelm Tetens; Hein Van Poppel
Journal:  Eur Urol       Date:  2007-04-18       Impact factor: 20.096
View more
  1 in total

1.  A PEG-Based Hydrogel for Effective Wound Care Management.

Authors:  Sen-Lu Chen; Ru-Huei Fu; Shih-Fei Liao; Shih-Ping Liu; Shinn-Zong Lin; Yu-Chi Wang
Journal:  Cell Transplant       Date:  2018-02       Impact factor: 4.064
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.